The Predictability of CD19 Expression Across Primitive Cellular Fractions of Relapsed B-ALL on Outcomes of CD19-targeted CAR T-cells

Clinical trial NCT06993766 · NOT_YET_RECRUITING

Trial details

NCT number: NCT06993766
Sponsor: King Faisal Specialist Hospital & Research Center
Status: NOT_YET_RECRUITING
Study type: OBSERVATIONAL

Relapsed B-ALL CAR T-cells CD19-directed CAR T-cell Therapy

Start date: 2025-05-20
Primary completion: 2030-05-01
Enrollment: 100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.